2-(N,N-Dimethylamino)-4-nitrophenyl-phosphat | 55428-51-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 英文名称: 2-(N,N-Dimethylamino)-4-nitrophenyl-phosphat
• 英文别名: 2-(Dimethylamino)-4-nitrophenyl dihydrogen phosphate；[2-(dimethylamino)-4-nitrophenyl] dihydrogen phosphate
• CAS: 55428-51-8
• 化学式: C₈H₁₁N₂O₆P
• 分子量: 262.159
• InChiKey: PZMJLAMSOBSEEJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  116
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-Dimethylamino-4-nitro-phenol; hydrochloride 在 potassium chloride 、 三氯氧磷 作用下， 生成 2-(N,N-Dimethylamino)-4-nitrophenyl-phosphat
  参考文献：
  名称：

  Synthetic studies on phosphorylating reagent. II. 2-(N,N-Dialkylamino)-4-nitrophenyl phosphate and its use in the synthesis of phosphate esters

  摘要：

  DOI：

  10.1021/jo00904a010

文献信息

• Naphthoquinone derivatives for the treatment of parasitic infections
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0537947A1

  公开（公告）日：1993-04-21

  The present invention relates to novel naphthoquinones of formula (I): wherein R³ is a C₁₋₃₅ non-aromatic hydrocarbon residue optionally substituted by one or more substituents selected from halo, C₁₋₆ alkoxy, hydroxy, phenyl, phenyl-C₁₋₆alkoxy and phenyl-C₁₋₆alkyl, each such phenyl group or mainly being optionally substituted by one or more groups selected from C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆alkoxy-C₁₋₆alkyl, hydroxy, halogen, halo-C₁₋₆alkyl, amine and mono- or di-C₁₋₄alkyl-amino; and    either the dotted line represents a double bond between the 2 and 3 positions of the naphthyl ring, R¹ and R⁴ each represent =O, and R² represents a phosphate group wherein R⁵ and R⁶ which may be the same or different, each represent a hydrogen atom or a C₁₋₆ alkyl group;    or the dotted line represents double bonds between the 1,2 and 3,4 positions of the naphthyl ring, and R¹, R² and R⁴ each represent a phosphate group         -OP(O)(OR⁵)(OR⁶) (wherein R⁵ and R⁶ are as hereinbefore described) and physiologically acceptable salts thereof. The compounds of formula (I) are useful in the treatment of parasitic infections.

  本发明涉及公式（I）的新萘醌： 其中R³是C₁₋₃₅非芳香烃碳氢残基，可选择性地被一个或多个取代基所取代，所述取代基选自卤素，C₁₋₆烷氧基，羟基，苯基，苯基-C₁₋₆烷氧基和苯基-C₁₋₆烷基，每个苯基或主要是可选择性地被一个或多个选自C₁₋₆烷氧基，C₁₋₆烷基，C₁₋₆烷氧基-C₁₋₆烷基，羟基，卤素，卤基-C₁₋₆烷基，胺和单或二-C₁₋₄烷基氨基的基团所取代；且点线表示萘环的2和3位置之间的双键，R¹和R⁴各自表示=O，R²表示磷酸酯基团，其中R⁵和R⁶可以相同或不同，分别表示氢原子或C₁₋₆烷基；或者点线表示萘环的1,2和3,4位置之间的双键，R¹，R²和R⁴各自表示磷酸酯基团-OP（O）（OR⁵）（OR⁶）（其中R⁵和R⁶如上所述），以及其生理上可接受的盐。 公式（I）的化合物在治疗寄生虫感染方面非常有用。
• Diagnostic and therapeutic compositions for alzheimer's disease
  申请人：MITOKOR

  公开号：US20030087858A1

  公开（公告）日：2003-05-08

  The present invention relates to genetic mutations in mitochondrial cytochrome c oxidase genes that segregate with Alzheimer's disease (AD). The invention provides methods for detecting such mutations, as a diagnostic for Alzheimer's Disease, either before or after the onset of clinical symptoms. The invention further provides treatment of cytochrome c oxidase dysfunction.

  本发明涉及与阿尔茨海默病（AD）相关的线粒体细胞色素c氧化酶基因的遗传突变。该发明提供了检测这种突变的方法，作为阿尔茨海默病的诊断方法，无论是在临床症状出现之前还是之后。本发明还提供了治疗细胞色素c氧化酶功能障碍的方法。
• CYCLOSPORIN PHOSPHATE DERIVATIVES AND MEDICINAL COMPOSITION
  申请人：NIPPON SHINYAKU COMPANY, LIMITED

  公开号：EP0852233A1

  公开（公告）日：1998-07-08

  The invention provides a novel cyclosporin compound which is water-soluble, improved in the amount of absorption and absorption rate after oral administration, with low nephrotoxicity, and a pharmaceutical composition comprising the same compound. The compound of the invention includes such cyclosporin phosphate derivatives as [phosphonothreonine2]cyclosporin A, [phosphono-4-hydroxynorvaline2]cyclosporin A, [phosphono-D-serine8]cyclosporin A, [phosphonothreonine2, phosphono-D-serine8]cyclosporin A, etc. or salts thereof, and solvates thereof.

  本发明提供了一种新型环孢素化合物，该化合物具有水溶性，口服后吸收量和吸收率均有所改善，肾毒性低，还提供了包含该化合物的药物组合物。 本发明的化合物包括[phosphonothreonine2]cyclosporin A、[phosphono-4-hydroxynorvaline2]cyclosporin A、[phosphono-D-serine8]cyclosporin A、[phosphonothreonine2，phosphono-D-serine8]cyclosporin A 等环孢素磷酸衍生物或其盐类，以及其溶液。
• 1,1,2-TRIARYL-1-BUTENE DERIVATIVES
  申请人：TAIHO PHARMACEUTICAL COMPANY LIMITED

  公开号：EP0272330B1

  公开（公告）日：1991-05-22
• EP0751951A4
  申请人：——

  公开号：EP0751951A4

  公开（公告）日：2000-05-03